Zobrazeno 1 - 10
of 793
pro vyhledávání: '"MICHAEL R. HARRISON"'
Autor:
Wolfgang Beckabir, Mi Zhou, Jin Seok Lee, Steven P. Vensko, Mark G. Woodcock, Hsing-Hui Wang, Sara E. Wobker, Gatphan Atassi, Alec D. Wilkinson, Kenneth Fowler, Leah M. Flick, Jeffrey S. Damrauer, Michael R. Harrison, Karen P. McKinnon, Tracy L. Rose, Matthew I. Milowsky, Jonathan S. Serody, William Y. Kim, Benjamin G. Vincent
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-14 (2024)
Abstract Neoadjuvant cisplatin-based chemotherapy is standard of care for muscle-invasive bladder cancer (MIBC). Immune checkpoint inhibition (ICI) alone, and ICI in combination with chemotherapy, have demonstrated promising pathologic response (
Externí odkaz:
https://doaj.org/article/20a284baf2454780aedd68c631ea83b7
Autor:
Elle C. Moore, Gerard C. Blobe, Nicholas C. DeVito, Brent A. Hanks, Michael R. Harrison, Christopher J. Hoimes, Jingquan Jia, Michael A. Morse, Parvathy Jayaprakasan, Andrew MacKelfresh, Hillary Mulder, Adam J. Hockenberry, Alia Zander, Martin C. Stumpe, Jackson Michuda, Kyle A. Beauchamp, Eric Perakslis, Timothy Taxter, Daniel J. George
Publikováno v:
Cancer Medicine, Vol 12, Iss 19, Pp 19394-19405 (2023)
Abstract Background Roughly 5% of metastatic cancers present with uncertain origin, for which molecular classification could influence subsequent management; however, prior studies of molecular diagnostic classifiers have reported mixed results with
Externí odkaz:
https://doaj.org/article/b59390dd42bb4274953a6323c81735b6
Publikováno v:
Frontiers in Surgery, Vol 10 (2023)
Since the 1970s, magnetic force has been used to augment modern surgical techniques with the aims of minimizing surgical trauma and optimizing minimally-invasive systems. The majority of current clinical applications for magnetic surgery are largely
Externí odkaz:
https://doaj.org/article/a16e9ecd15824edeb8f9f453fcece622
Autor:
Michael R. Harrison
Publikováno v:
Panorama, Vol 9, Iss 1 (2023)
Externí odkaz:
https://doaj.org/article/0d9f61f8ad5c4a3f9c314cc5d0831cbc
Autor:
Karen A. Autio, Emmanuel S. Antonarakis, Tina M. Mayer, Daniel H. Shevrin, Mark N. Stein, Ulka N. Vaishampayan, Michael J. Morris, Susan F. Slovin, Elisabeth I. Heath, Scott T. Tagawa, Dana E. Rathkopf, Matthew I. Milowsky, Michael R. Harrison, Tomasz M. Beer, Arjun V. Balar, Andrew J. Armstrong, Daniel J. George, Channing J. Paller, Arlyn Apollo, Daniel C. Danila, Julie N. Graff, Luke Nordquist, Erica S. Dayan Cohn, Kin Tse, Nicole A. Schreiber, Glenn Heller, Howard I. Scher
Publikováno v:
European Urology Open Science, Vol 34, Iss , Pp 70-78 (2021)
Background: Phase 2 trial endpoints that can be utilized in high-risk biochemical recurrence (BCR) after prostatectomy as a way of more rapidly identifying treatments for phase 3 trials are urgently needed. The efficacy of abiraterone acetate plus pr
Externí odkaz:
https://doaj.org/article/7cb29db5a1d04ef391276d51f770d34a
Autor:
Hannah Dzimitrowicz, Elizabeth Esterberg, LaStella Miles, Giovanni Zanotti, Azah Borham, Michael R. Harrison
Publikováno v:
Cancer Medicine, Vol 10, Iss 24, Pp 8891-8898 (2021)
Abstract Background It is unclear whether patients with renal cell carcinoma (RCC) are routinely assessed for recurrence risk post‐nephrectomy and whether patients at high recurrence risk are seen by providers who can evaluate candidacy for adjuvan
Externí odkaz:
https://doaj.org/article/6932471d1f104377b8b3309cf1069065
Autor:
Matthew D. Tucker, Landon C. Brown, Yu-Wei Chen, Chester Kao, Nathan Hirshman, Emily N. Kinsey, Kristin K. Ancell, Kathryn E. Beckermann, Nancy B. Davis, Renee McAlister, Kerry Schaffer, Andrew J. Armstrong, Michael R. Harrison, Daniel J. George, W. Kimryn Rathmell, Brian I. Rini, Tian Zhang
Publikováno v:
Biomarker Research, Vol 9, Iss 1, Pp 1-9 (2021)
Abstract Background The identification of biomarkers to select patients with metastatic renal cell carcinoma (mRCC) most likely to respond to combination immunotherapy (IO) is needed. We sought to investigate an association of the baseline neutrophil
Externí odkaz:
https://doaj.org/article/046d21ea12ea41aeaea7c6d824b8b8a6
Autor:
Andrew L. Laccetti, Benjamin Garmezy, Lianchun Xiao, Minas Economides, Aradhana Venkatesan, Jianjun Gao, Eric Jonasch, Paul Corn, Amado Zurita‐Saavedra, Landon C. Brown, Chester Kao, Emily N. Kinsey, Rajan T. Gupta, Michael R. Harrison, Andrew J. Armstrong, Daniel J. George, Nizar Tannir, Pavlos Msaouel, Amishi Shah, Tian Zhang, Matthew T. Campbell
Publikováno v:
Cancer Medicine, Vol 10, Iss 7, Pp 2341-2349 (2021)
Abstract Introduction Two separate antiangiogenic tyrosine kinase inhibitors (TKIs) and immunotherapy (IO) combinations are FDA‐approved as front‐line treatment for metastatic renal cell carcinoma (mRCC). Little is known about off‐protocol and
Externí odkaz:
https://doaj.org/article/93fb0ccf60b5470ca6cdd487ce1a82ce
Autor:
Eric Powers, Georgia Sofia Karachaliou, Chester Kao, Michael R. Harrison, Christopher J. Hoimes, Daniel J. George, Andrew J. Armstrong, Tian Zhang
Publikováno v:
Journal of Hematology & Oncology, Vol 13, Iss 1, Pp 1-13 (2020)
Abstract Metastatic castration-resistant prostate cancer (mCRPC) remains a terminal diagnosis with an aggressive disease course despite currently approved therapeutics. The recent successful development of poly ADP-ribose polymerase (PARP) inhibitors
Externí odkaz:
https://doaj.org/article/798f2641d2d84fc38d531bd96beebc49
Autor:
Yu-Wei Chen, Matthew D. Tucker, Landon C. Brown, Hesham A. Yasin, Kristin K. Ancell, Andrew J. Armstrong, Kathryn E. Beckermann, Nancy B. Davis, Michael R. Harrison, Elizabeth G. Kaiser, Renee K. McAlister, Kerry R. Schaffer, Deborah E. Wallace, Daniel J. George, W. Kimryn Rathmell, Brian I. Rini, Tian Zhang
Publikováno v:
Cancers, Vol 14, Iss 15, p 3830 (2022)
A lower baseline neutrophil-to-eosinophil ratio (NER) has been associated with improved responses to immune checkpoint inhibitors (ICI)-treated metastatic renal cell carcinoma (mRCC). This study investigated the decrease in NER at week 6 after ipilim
Externí odkaz:
https://doaj.org/article/43555838543249378a02c98f16f46bbf